Yes you did miss something: "In addition, Amarant
Post# of 30027
"In addition, Amarantus received an exclusive, five (5) year option to license any severe burn-related products developed by Regenicin. Amrantus can exercise this option at a cost of $10,000,000 USD plus a royalty of 5% on gross revenues in excess of $150M USD."
http://ir.amarantus.com/all-sec-filings/conte...069314.pdf